Overview:
The purpose of this phase 1 study being conducted by the Stem Cell Institute in Panama is to assess the safety and effectiveness of donor (allogeneic) umbilical cord mesenchymal stem cells (MSC’s) administered to patients with multiple sclerosis (MS). The study commenced in January 2014 and aims to recruit 20 patients between the age of 18 and 55 years with MS. Participants will receive an intravenous injection of MSC’s once a day for 7 days and will be followed up after treatment to determine the therapeutic effect at 4, 12 and 52 weeks. Participants will be evaluated post treatment by neurological assessments: walking time, quality of life survey, and MRI scans of the brain and cervical (neck region) spinal cord. The estimated completion date is August 2017.
Location: Panama City, Panama
Trial design: Safety and efficacy
Status: Recruiting
Find out more